Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | SEA domain containing protein | 0.0025 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0025 | 0.5 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.5 | 0.5 |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.0025 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0025 | 0.5 | 0.5 | |
Onchocerca volvulus | 0.0025 | 0.5 | 0.5 | |
Onchocerca volvulus | 0.0025 | 0.5 | 0.5 | |
Onchocerca volvulus | 0.0025 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.